Publications

Publications

  1. Polis B, Gil-Henn H (2018) Commentary on Giralt et al.: PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer’s disease. Exp Neurol. pii: S0014-4886(18)30398-4. DOI: 10.1016/j.expneurol.2018.08.011.
  2. Meirson T, Gil-Henn H (2018) Targeting invadopodia for blocking breast cancer metastasis. Drug Resist Updat. 39:1-17. DOI: 10.1016/j.drup.2018.05.002.
  3. Goertzen C, Mahdi H, Laliberte C, Meirson T, Eymael D, Gil-Henn H, Magalhaes M (2018) Oral inflammation promotes oral squamous cell carcinoma invasion. Oncotarget 9, 29047-29063. DOI: 10.18632/oncotarget.25540.
  4. Meirson T, Genna A, Lukic N, Makhnii T, Alter J, Sharma VP, Wang Y, Samson AO, Condeelis JS, Gil-Henn H (2018) Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget 9 ,22158-22183. DOI: 10.18632/oncotarget.25243.
  5. Genna A, Lapetina S, Lukic N, Twafra S, Meirson T, Sharma VP, Condeelis JS, Gil-Henn H (2018) Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells. J Cell Biol 217, 375-395. DOI: 10.1083/jcb.201702184.
  6. Meirson T, Samson AO, Gil-Henn H (2017) An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2. Drug Des Devel Ther 11, 1535-1557. DOI: 10.2147/DDDT.S136150.
  7. Manikoth Ayyathan D, Ilić N, Gil-Henn H, Blank M (2017) Generation of SMURF2 knockout human cells using the CRISPR/Cas9 system. Anal Biochem 531, 56-59. DOI: 10.1016/j.ab.2017.05.024.
  8. Rosenberg BJ, Gil-Henn H, Mader CC, Halo T, Yin T, Condeelis J, Machida K, Wu YI, Koleske AJ (2017) Phosphorylated cortactin recruits Vav2 guanine nucleotide exchange factor to activate Rac3 and promote invadopodial function in invasive breast cancer cells. Mol Biol Cell 28, 1347-1360. DOI: 10.1091/mbc.E16-12-0885.
  9. Roman Samsonov, Vladimir Burdakov, Tatiana Shtam, Zamira Radzhabova, Dmitry Vasilyev, Evgenia Tsyrlina, Sergey Titov, Michail Ivanov, Lev Berstein, Michael Filatov, Nikolay Kolesnikov, Hava Gil-Henn, Anastasia Malek (2016) Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer. Tumour Biology 37, 12011-12021. DOI: 10.1007/s13277-016-5065-3.
  10. Ben-Chetrit N, Chetrit D, Russell R, Körner C, Mancini M, Abdul-Hai A, Itkin T, Carvalho S, Cohen-Dvashi H, Koestler WJ, Shukla K, Lindzen M, Kedmi M, Lauriola M, Shulman Z, Barr H, Seger D, Ferraro DA, Pareja F, Gil-Henn H, Lapidot T, Alon R, Milanezi F, Symons M, Ben-Hamo R, Efroni S, Schmitt F, Wiemann S, Caldas C, Ehrlich M, Yarden Y (2015) Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Science Signaling 8, ra7. DOI: 10.1126/scisignal.2005537.
  11. Gil-Henn H, Patsialou A, Wang Y, Warren MS, Condeelis JS, Koleske AJ (2013) Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo. Oncogene 32, 2622-30. DOI: 10.1038/onc.2012.284.
  12. Sibony-Benyamini H, Gil-Henn H (2012) Invadopodia: the leading force. Eur J Cell Biol 91, 896-901. DOI: 10.1016/j.ejcb.2012.04.001.
  13. Magalhaes MA, Larson DR, Mader CC, Bravo-Cordero JJ, Gil-Henn H, Oser M, Chen X, Koleske AJ, Condeelis J (2011)  Cortactin phosphorylation regulates cell invasion through a pH-dependent pathway. J Cell Biol 195, 903-20. DOI: 10.1083/jcb.201103045.
  14. Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ, Gil-Henn H (2011)  An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion.Cancer Research 71, 1730-41. DOI: 10.1158/0008-5472.CAN-10-1432.
  15. Oser M, Mader CC, Gil-Henn H, Magalhaes M, Bravo-Cordero JJ, Koleske AJ, Condeelis J (2010) Specific tyrosine phosphorylation sites on cortactin regulate Nck1-dependent actin polymerization in invadopodia. J Cell Sci 123, 3662-73. DOI: 10.1242/jcs.068163.
  16. Wang L, Tassiulas I, Park-Min KH, Reid AC, Gil-Henn H, Schlessinger J, Baron R, Zhang JJ, Ivashkiv LB (2008)  ‘Tuning’ of type I interferon-induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages. Nature Immunology 9, 186-93. DOI: 10.1038/ni1548.
  17. Gil-Henn H, Destaing O, Sims NA, Aoki K, Alles N, Neff L, Sanjay A, Bruzzaniti A, De Camilli P, Baron R, Schlessinger J (2007) Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2(-/-) mice. J Cell Biol 178, 1053-64. DOI: 10.1083/jcb.200701148.
  18. Levitin F, Stern O, Weiss M, Gil-Henn H, Ziv R, Prokocimer Z, Smorodinsky NI, Rubinstein DB, Wreschner DH (2005) The MUC1 SEA module is a self-cleaving domain. J Biol Chem 280, 33374-86. DOI: 10.1074/jbc.M506047200.
  19. Toledano-Katchalski H, Kraut J, Sines T, Granot-Attas S, Shohat G, Gil-Henn H, Yung Y, Elson A (2003) Protein tyrosine phosphatase epsilon inhibits signaling by mitogen-activated protein kinases. Mol Cancer Res 1, 541-50.
  20. Gil-Henn H, Elson A (2003) Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells.J Biol Chem 278, 15579-86. DOI: 10.1074/jbc.M210273200.
  21. Gil-Henn H, Volohonsky G, Elson A (2001)  Regulation of protein-tyrosine phosphatases alpha and epsilon by calpain-mediated proteolytic cleavage. J Biol Chem  276, 31772-9. DOI: 10.1074/jbc.M103395200.
  22. Gil-Henn H, Volohonsky G, Toledano-Katchalski H, Gandre S, Elson A (2000) Generation of novel cytoplasmic forms of protein tyrosine phosphatase epsilon by proteolytic processing and translational control.Oncogene 19, 4375-84. DOI: 10.1038/sj.onc.1203790.
  23. Peretz A*, Gil-Henn H*, Sobko A, Shinder V, Attali B, Elson A (2000) Hypomyelination and increased activity of voltage-gated K(+) channels in mice lacking protein tyrosine phosphatase epsilon.EMBO 19, 4036-45.  DOI: 10.1093/emboj/19.15.4036. * Equal contribution